Loading clinical trials...

Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion | Clinical Trials | Clareo Health

COMPLETEDNA

Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion

Comparison of Intravitreal Bevacizumab and Triamcinolone Acetonide With Intravitreal Bevacizumab Alone in Macular Edema Secondary to Central Retinal Vein Occlusion

NCT04812977•Hayatabad Medical Complex

View on ClinicalTrials.gov

Summary

To compare the effect of intravitreal-Bevacizumab and Triamcinolone with intravitreal-Bevacizumab alone on visual acuity and central foveal thickness in patients with macular edema secondary to central retinal vein occlusion.

Eligibility

Age

40 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects of either gender, age 40-80 years, having macular edema secondary to CRVO, Best-corrected visual acuity (BCVA) of less than or equal to 0.3 on Log MAR chart (Snellen equivalent of 6/12), Central foveal thickness CFT greater than or equal to 250 microns on Heidelberg Spectralis Spectral Domain Optical coherence tomography (SD-OCT) and clinical diagnosis of CRVO.

Exclusion Criteria

•previously received laser treatment and/or intravitreal injection of any Anti-VEGF agent, having one eye, diagnosed case of glaucoma, family history of glaucoma, young patient, and anyone who has received any treatment for CRVO before presenting to us.

Locations (1)

Hayatabad Medical Complex

Peshawar, KPK, Pakistan

Key Dates

Start Date

June 10, 2018

Primary Completion Date

December 10, 2018

Completion Date

December 10, 2018

Last Updated

October 3, 2022

Enrollment

ACTUAL participants

Conditions

Central Retinal Vein Occlusion With Macular Edema

Interventions

Group A

DRUG

Ocular Safety and Usability Study for FYB203 PFS

NCT06708637

View study

COMPLETEDPHASE1/PHASE2

Phase 1 Open-label Study to Evaluate Efficacy and Tolerability of TLC399 in Patients With Macular Edema Due to RVO

NCT02006147

Central Retinal Vein Occlusion With Macular EdemaBranch Retinal Vein Occlusion With Macular Edema

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 3, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion

Inclusion Criteria

Exclusion Criteria

Ocular Safety and Usability Study for FYB203 PFS

Phase 1 Open-label Study to Evaluate Efficacy and Tolerability of TLC399 in Patients With Macular Edema Due to RVO

Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas